Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Go back to Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 11.42 +0.24 (2.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.18 | 52 Week High | $1.45 | |||
| Open | $10.88 | 52 Week Low | $0.50 | |||
| Day High | $12.23 | P/E | N/A | |||
| Day Low | $10.86 | EPS | $0.00 | |||
| Volume | 2,963,972 | |||||
